obesity drug news today glp-1 october 27 2025 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits McKee's proposed FY2027 budget drops

Whether youre an athlete, entrepreneur, or biohacker, the core of his longevity stack is accessible and effective

J Clin Oncol, 2021 Gastrointestinal Cancers Symposium 39(suppl 3), 2021

Among patients who previously used a GLP-1-based medication, most switched from injectable anti-obesity medications (AOM), including injectable AOM semaglutide (sold as Wegovy) and AOM tirzepatide (sold as Zepbound)

Specifically, GHK-Cu activates TGF-beta/SMAD-mediated collagen synthesis and extracellular matrix remodeling through copper-dependent enzyme pathways

the extant literature is dominated by inositol-centric trials with limited testing of vitamin D interactions